UN Resolution on Journalist Safety Passed, But Long Way to Go

Kashmiri journalists at a rare protest against a government clampdown on freedom of expression in 2012. Credit: Athar Parvaiz/IPS

Kashmiri journalists at a rare protest against a government clampdown on freedom of expression in 2012. Credit: Athar Parvaiz/IPS

By Tharanga Yakupitiyage
UNITED NATIONS, Sep 30 2016 (IPS)

The UN Human Rights Council (UNHRC) advanced its commitment to the safety of journalists after adopting a groundbreaking resolution with measures for states to ensure journalist protection. But this is only the first step, many note.

Though the UNHRC has adopted resolutions on the safety of journalists in the past, some note that this year’s resolution is more comprehensive in protecting the rights of freedom of expression and the press.For the first time, UNHRC called for states to release arbitrarily detained journalists and to reform laws that are misused to hinder their work.

“[The resolution] brings up these issues more explicitly than it has been brought up in other resolutions,” Committee to Protect Journalists’ (CPJ) Advocacy Director Courtney Radsch told IPS.

She stressed that the resolution acknowledges the role that states play in committing violence against journalists and in creating a permissive environment for the safety of journalists.

“It is not simply enough to talk about the safety of journalist without also addressing the need to create an environment in which freedom of expression and press freedom can flourish,” she stated.

Reporters Without Borders’ (RSF) Advocacy and Communications Officer Margaux Ewen echoed similar sentiments to IPS, noting that the resolution is a “wonderful reiteration” which calls on member states to implement their international obligations.

For the first time, UNHRC called for states to release arbitrarily detained journalists and to reform laws that are misused to hinder their work.

According to CPJ, approximately 200 journalists were imprisoned worldwide in 2015. The organisation recorded the highest number of such arrests in China, where 49 journalists were imprisoned. Most recently, Chinese journalists Lu Yuyu and Li Tingyu were detained in June 2016 on suspicion of “picking quarrels and provoking trouble.” They had been documenting and reporting on protests across the East Asian nation since 2012.

China is among the members of UNHRC.

The newly adopted resolution also affirms the right of journalists to use encryption and anonymity tools. Journalists often rely on such mechanisms to safely impart information anonymously online. They are also used to encrypt their communications in order to protect their contacts and sources.

Radsch noted that these tools are essential for journalists “to do their job in the 21st century.”

The resolution also addresses the specific risks that women journalists face in their work, condemning all gender-based attacks.

Earlier in September, freelance journalist Gretchen Malalad and Al Jazeera Correspondent Jamela Alindogan-Caudron were subject to severe social media attacks, receiving threats of rape and death due to their coverage of the Philippine government’s controversial anti-drug war.

The National Union of Journalists of the Philippines (NJUP) Ryan Rosauro expressed his dismay of the state of journalism in the country, stating: “We will never take any threats, whether of physical harm or to silence us, lightly for we have lost far too many of our colleagues and hardly seen justice for them,” he said.

In a joint statement with NJUP, the International Federation of Journalists (IFJ) stated that the government must take social media threats to journalists seriously and should penalise perpetrators to ensure the safety of journalists.

In their 2016 World Press Freedom Index, RSF ranked the Philippines 138th out of 180 countries in press freedom making it one of the most dangerous countries for practicing journalists.

As in previous years, the UNHRC also highlighted the need to end violence against journalists and to combat impunity for attacks.

CPJ found that over 1,200 journalists have been killed since 1992, the majority of whom were murdered with complete impunity. Other organisations speculate that the numbers are higher, with IFJ reporting that at least 2,300 journalists and media staff have been killed since 1990.

In 2009, prominent Sri Lankan journalist and editor Lasantha Wickramatunga was beaten to death after his car was pulled over by eight helmeted men on motorcycles. Often critical of the government and its conduct in the country’s civil war, the editor had been attacked before and received death threats for months prior to his death. He even anticipated his own fate, writing an essay shortly before his death about free media in the South Asian nation.

“In the course of the past few years, the independent media have increasingly come under attack. Electronic and print-media institutions have been burnt, bombed, sealed and coerced. Countless journalists have been harassed, threatened and killed. It has been my honour to belong to all those categories and now especially the last,” Wickramatunga wrote.

Most recently, Jordanian journalist Nahed Hattar was shot dead while on his way to face charges for sharing a cartoon deemed offensive to Islam.

“The killing of Mr. Hattar is appalling, and it is unacceptable that no protection measures had been put in place to ensure his safety, particularly when the threats against him were well known to the authorities,” said UN special rapporteur on freedom of opinion and expression David Kaye.

Kaye urged authorities to bring the perpetrator to justice and to ensure legislation that allows a culture of diverse expression.

However, both Radsch and Ewen noted that the resolution is only the first step as it must be translated to action on the ground.

“We continue to see the failure of states to adequate investigate the murders of journalists…so while resolutions are important, we need to see actual concrete actions to accompany these normative statements,” Radsch told IPS.

Ewen stated that UN resolutions are “strong and strongly worded” but it still remains to be seen for states to implement measures to protect journalists and the right of freedom of expression. She pointed to RSF’s campaign to create a Special Representative to the UN Secretary-General for the safety of journalists as a way to ensure states comply with their international obligations.

Led by RSF, the Protect Journalists campaign has brought together over a 100 media organisations and human rights organisations including CPJ, the Guardian and the United Nations Correspondents Association to push for the establishment of a special representative.

During a press conference, RSF Secretary General Christophe Deloire noted that a special representative could act as an early warning and rapid response mechanism to give journalists, when threatened, access to authorities and protective measures as laid out in the resolution. He also added that a special representative with political weight can make sure the safety of journalists is integrated in all UN programs and operations.

“Every week, there are new names on new graves in journalist cemeteries…we cannot let anymore journalists be killed because of this lack of political will,” Deloire told press.

The 47-member state council adopted the resolution on the safety of journalists by consensus, expressing a deep concern for the increased number of journalists and media workers who have been killed, tortured and detained. Nations beyond the UNHRC including Austria and the United States also joined the initiative as cosponsors.

 

Move Over, Cuba: The World's Finest Cigars Are Using African Tobacco

EASTON, PA—(Marketwired – September 29, 2016) – Cigar Advisor, the nation's premiere online cigar magazine, proudly serves cigar enthusiasts with a uniquely down–to–earth perspective on the enjoyment of premium cigars. The magazine has published “5 Things You Need to Know About…Cameroon Wrapper,” a point–by–point review of important facts about the qualities of “genuine” Cameroon cigar tobacco, how it's grown and why it's found as an ingredient on some of the world's top non–Cuban cigars. The latest edition of the magazine's “5 Things” series is authored by Cigar Advisor Managing Editor John Pullo, and highlights a number of premium cigars that use this in–demand, yet very expensive leaf in their hand–made construction.

“If you smoke cigars – even just occasionally – these are five things that will change your outlook on cigars with a Cameroon wrapper,” said John Pullo, Cigar Advisor Managing Editor. John has just added to the online cigar magazine's “5 Things” series, this time a primer on the African nation of Cameroon. He calls Cameroon wrapper tobacco a “secret weapon leaf” for cigar blenders who are trying to coax more flavor from traditionally mild tobaccos: “There are hints of pepper and leather, but [Cameroon is] dominated by a toasty, woody tone and a subtle sweetness that's more of the toasty and buttery variety, especially in the aroma. Very smooth.” It's that intensity and mix of flavor, John writes, that make it well worth a cigar smoker's while to search out a good Cameroon–clad cigar – more flavor is imparted to the smoke because of an abundance of natural oils, resulting in what he calls “a more savory quality” to the smoke. “Few do it better than Cameroon,” he writes.

John stresses the importance of cigar enthusiasts “discovering” this rare leaf by trying a number of different cigars that feature it, including selections from CAO, Partagas and Arturo Fuente Hemingway cigars, as well as big ring gauge selections from Perdomo, Rocky Patel and Nub. “Genuine Cameroon (raised in Africa) leaf tends to be smaller – and therefore, so are the cigars it's used on,” he writes, noting the limited selection of larger cigars on which this wrapper is used. “Only the best cigar rollers can stretch Cameroon wrapper to these limits,” he says.

The Cigar Advisor also examines the infrastructure difficulties in transporting tobacco out of the country, the challenges in growing more leaf to meet demand and how this particular strain of tobacco almost went extinct. “It's difficult to do business in remote areas of Africa. But there is a beauty to [the country's] simplicity, as the far reaches of Cameroon feature a temperate climate that is perfect for wrapper growing,” John notes.

To learn the “Five Things You Need to Know About…Cameroon Wrappers” and see the recommended cigars that use it, go to CigarAdvisor.com.

About Cigar Advisor Magazine:

Cigar Advisor magazine is a digital publication created by, and for, real cigar enthusiasts. The Editors strive every day to accomplish three goals: welcome novices to the hobby of cigar smoking with advice and open arms; share their tobacco–rich lifestyle with good friends and veteran smokers alike; and profess their love for a good smoke with cigar enthusiasts of all stripes, from around the world. Cigar smokers are a passionate bunch – and whether it is food, drink, sports or cigars they're fanatical about, Cigar Advisor shares those passions with a razor–sharp edge. Find that passion and more on display at Cigar Advisor.

Image Available: http://www.marketwire.com/library/MwGo/2016/9/28/11G116067/Images/CACover_5Cameroon–fbcfe176990a863d9190ad6a091ac200.jpg

Vernalis PLC Announces Results Announcement for the 12 Months Ended 30 June 2016

WINNERSH, UNITED KINGDOM—(Marketwired – Sep 29, 2016) – Vernalis PLC (LSE: VER) (OTC PINK: VNLPY)

29 September 2016
LSE: VER

Vernalis plc
Results Announcement for the 12 months ended 30 June 2016

Significant investment in Tuzistra® XR US launch as transition to a commercial specialty pharmaceutical company continues

Vernalis plc (LSE: VER) today announces its audited results for the 12 month period ended 30 June 2016.

    (Audited)
12 months
ended
30 June
2016
£000
  (Unaudited)
12 months
ended
30 June
2015
£000
  (Audited)
18 months
ended
30 June
2015*
£000
Revenue   12,034   13,712   19,882
Sales and marketing expenditure   (20,428)    
Research and development expenditure   (10,932)   (15,687)   (22,563)
General and administrative expenditure (before exceptional items)   (5,289)   (6,019)   (8,635)
Operating loss            
  Before exceptional items   (26,223)   (8,224)   (12,078)
  After exceptional items   (23,572)   (7,981)   (11,835)
Net finance income   8,273   4,252   2,576
Loss before tax            
  Before exceptional items   (17,950)   (3,972)   (9,502)
  After exceptional items   (15,299)   (3,729)   (9,259)
Income tax credit   804   1,946   2,858
Loss after tax            
  Before exceptional items   (17,146)   (2,026)   (6,644)
  After exceptional items   (14,495)   (1,783)   (6,401)
Cash resources   84,018   61,258   61,258
             

*The Group changed its accounting reference date from 31 December to 30 June on 18 November 2014 to align the external reporting period with the seasonality of the US cough cold market, which will become a major component of the Group's commercial business. While the financial highlights and financial review below focus on the audited 12 months ended 30 June 2016 compared to the unaudited 12 months ended 30 June 2015, figures for the audited 18 month period to 30 June 2015 are also presented. 

Financial Highlights for the 12 months ended 30 June 2016

  • Revenue was £12.0 million (2015: £13.7 million):
    • Tuzistra® XR net revenue was £1.1 million and represents deliveries mad e to wholesalers by 30 June 2016
    • Research collaboration income was flat at £8.0 million (2015: £7.9 million) but included an increase in FTE income offset by a reduction in milestone receipts. Our research organisation remained self–funded
    • As expected frovatriptan royalty income was lower than the prior year at £2.9 million (2015: £4.9 million); most of this decrease was due to a volume decline, with two 12.5kg batches of API delivered to Menarini during the 12 months to 30 June 2016 (2015: three 12.5kg batches of API)
      • Menarini's underlying sales for the 12 months to 30 June 2016 were down 18 per cent at EUR 20.8 million (2015: EUR 25.2 million)
      • As previously highlighted, major patent expiry occurred in December 2015 and subsequent generic entries have already started to impact both pricing and volumes
  • Operating costs before exceptional items were £36.6 million (2015: £21.7 million); the increase was due to the significant investment in Tuzistra® XR sales, marketing and other US commercial infrastructure
  • Pre–exceptional loss for the period was £17.1 million (2015: £2.0 million) and loss after exceptional items was £14.5 million (2015: £1.8 million), including an exceptional gain on the surrender of an onerous building lease; the increase in the loss was due to the additional operating costs in excess of gross margin following the launch of Tuzistra® XR
  • Cash resources including cash and cash equivalents and held to maturity assets increased by £22.8 million in the 12 months and included:
    • £38.9 million (net of expenses) equity placing completed in May 2016
    • $5.4 million (£3.7 million) payment for the acquisition of Moxatag®
    • £8.0 million foreign exchange gain on retranslation of US dollar and euro cash resources into sterling (2015: £4.1 million)
    • Underlying net cash burn increased to £21.8 million for the year (2015: £8.5 million)
  • Balance sheet remains strong with £84.0 million of cash resources and no debt at 30 June 2016

Operational Highlights
US Commercial Pipeline:

  • Tuzistra® XR, the only 12–hour, extended–release, codeine based cough cold suspension product, launched in the US ahead of the 2015/16 cough cold season
  • Focused US primary care sales force fully recruited, trained and deployed to the field
  • US rights to Moxatag®, the only US approved once–a–day formulation of amoxicillin, acquired in October 2015, validating the Company's ability to expand its US commercial portfolio
  • CCP–07 filed with FDA and accepted for review in September 2016. PDUFA date of 20 April 2017
  • CCP–08 pivotal single–dose and multiple dose comparative bioavailability studies successfully completed and NDA submission remains on track for calendar year 2016
  • Two further programmes in active development at Tris, with proof–of–concept (“POC”) now targeted during the 2016/17 financial year

Other:

  • NCE Development Pipeline: Completion of the Phase 2 POC study of V158866 in August 2015 which ended in–house investment in NCE pipeline
  • Corvus Pharmaceuticals, Inc. announced (in January 2016) as the worldwide licensee for the adenosine antagonist programme with CPI–444 (formerly V81444), initially being developed for immuno–oncology with clinical studies expected in 2016
  • RedoxTherapies, our partner for vipadenant (V2006), acquired by Juno Therapeutics Inc. (Juno), a leader in CAR[–T] and TCR technologies. Juno will continue to explore the utility of vipadenant in immuno–oncology
  • Verona Pharma plc announced positive phase II study results for RPL554 in COPD and raised £45 million via an equity placing
  • Research Collaborations: Six active collaborations during the year ended 30 June 2016; business remained self–funded

Expected 2016/17 Newsflow (all dates calendar year unless otherwise stated):

  • CCP–07: potential approval by FDA (Q2 2017 calendar year)
  • CCP–08: NDA submission (2016 calendar year )
  • Re–launch Moxatag® in the US market through our focused US primary care sales force (H2 2016 calendar year)
  • POCs on two remaining programmes in cough cold pipeline (CCP–05 and CCP–06) (during 2016/17 financial year)
  • Achieve milestones under existing collaborations
  • Secure new research collaborations
  • Continue to leverage our US commercial infrastructure with possible complementary new product acquisitions/in–licensing

Ian Garland, Chief Executive Officer, commented, “The last twelve months have seen a major transformation in our business as we launched the first product from our cough cold franchise, Tuzistra® XR, into the US market. We have made a significant investment in our commercial infrastructure to support the launch of Tuzistra® XR, and this will continue during the product's launch phase as we seek to gain a greater share of the US cough cold market. We will leverage this investment and our US commercial infrastructure to launch the once–a–day antibiotic, Moxatag® in the second half of 2016. The cough cold pipeline continues to mature with CCP–07 and CCP–08 on track for potential approvals in 2017.

Our cash position was bolstered following the recent equity raise to continue the promotional investment in Tuzistra® XR as well as launch Moxatag® and our additional products, CCP–07 and CCP–08 in the near term. We remain very excited about the growth potential of the business.”

Presentation & Conference Call
Vernalis management will host a presentation at 9.30am (UK) at the offices of FTI Consulting 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. It will also be available via webcast at http://www.vernalis.com/investor–centre/presentations–and–webcasts and www.cantos.com and via conference call, which can be joined by dialling: +44 (0) 20 3003 2666. Please contact Matthew Moss at FTI consulting +44 (0) 20 3727 1000 for details.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

— ends –

Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns–pdf.londonstockexchange.com/rns/1427L_1–2016–9–28.pdf

Enquiries:

Vernalis plc: +44 (0) 118 938 0015
Ian Garland, Chief Executive Officer  
David Mackney, Chief Financial Officer  
Canaccord Genuity Limited (Nominated Adviser and Joint Broker): +44 (0) 20 7523 8000
Dr Julian Feneley  
Rupert Winckler  
Henry Fitzgerald–O'Connor  
Emma Gabriel  
Shore Capital (Joint Broker): +44 (0)20 7408 4090
Bidhi Bhoma  
Toby Gibbs  
FTI Consulting: +44 (0) 20 3727 1000
Ben Atwell  
Simon Conway  

This information is provided by RNS
The company news service from the London Stock Exchange

Uncertainty Mars Potential for Peace in South Sudan

A delegation from the UN Security Council visited South Sudan at the beginning of September 2016. UN Photo/Isaac Billy.

A delegation from the UN Security Council visited South Sudan at the beginning of September 2016. UN Photo/Isaac Billy.

By Jonathan Rozen
UNITED NATIONS, Sep 28 2016 (IPS)

Nearly one month after UN Security Council members visited troubled South Sudan, disagreement reigns over even the limited outside measures proposed to try to bring the security situation in the world’s newest country under control.

“To fix South Sudan you will need 250,000 soldiers, you will need four or five billion dollars per year. Who is going to do that? Nobody.” Berouk Messfin, Senior Researcher with the Institute for Security Studies in Addis Ababa, told IPS.

While it is clear that neither an arms embargo nor an additional 4000 UN troops – two measures currently on the table – will be a panacea for troubled South Sudan, there is a slim hope that they may pressure the country’s leadership to act in the interests of its people.

As UN Secretary General Ban Ki-moon told a high-level meeting on South Sudan’s humanitarian situation on September 22: “Time and again, (South Sudan’s) leaders have resorted to weapons and identity politics to resolve their differences.”

For three days in early September Security Council members traveled to South Sudan. At the end of the visit a ‘joint communiqué’ was issued that seemingly brokered an agreement with the interim Transitional Government of National Unity. It outlined the strengthening of the existing 12,000-troop UN peacekeeping mission (UNMISS) through an additional 4000-troop Regional Protection Force, and the removal of restrictions to humanitarian access. But in the days since the communiqué, South Sudanese officials have insisted that specifics of the additional force remain unresolved.

“We have agreed in principle … but the details of their deployment, the countries that will contribute … that is the work that is left now,” Hussein Mar Nyuot, Minister of Humanitarian Affairs and Disaster Management for the South Sudan government told IPS. “I don’t see the difference that this [4000] will come and do.”

“To fix South Sudan you will need 250,000 soldiers, you will need four or five billion dollars per year. Who is going to do that? Nobody.” — Berouk Messfin, Institute for Security Studies.

The proposed additional force would be under the command of UNMISS and was endorsed in July by the east African Intergovernmental Authority on Development (IGAD) body leading the South Sudan peace talks. Building on UNMISS’ existing mandate, which already calls for the “use all necessary means” to protect UN personnel and civilians from threats, the Security Council believes the additional troops would strengthen the security situation.

The force is to be deployed as soon as possible, Hervé Ladsous, Under Secretary General for UN Peacekeeping Operations, told reporters Friday. Though he also said they were trying to elucidate “contradictory statements” from the capital, Juba.

In this context, human rights advocacy groups, along with UN Secretary General Ban Ki-moon, have continued their calls for the UN Security Council to impose an arms embargo to stop both sides’ continued militarization.

“It’s going to be more difficult for parties to the conflict to get access to ammunition and supplies,” Louis Charbonneau, UN Director for Human Rights Watch, told IPS. “Combine it with the boosting of UNMISS … [and] it’s going to make a difference for civilians.”

However, the South Sudanese government, whose soldiers have been implicated in ethnically motivated killings, rape, and looting, disagrees on the value of an embargo.

“[The] issue is not actually the arms that are coming … even if you have an arms embargo there are already arms in the hands of the local people … the arms that are coming in are not actually the ones causing any problems,” Hussein Mar Nyuot told IPS.

If they say they want to have [an] arms embargo, ok, but what will you do with the arms that are in the hands of the people?” he continued. “We should encourage the government to disarm the civilian population.”

Peacekeepers and UN police officers (UNPOL) with the UN Mission in South Sudan (UNMISS). Credit: UN Photo/Eric Kanalstein

Peacekeepers and UN police officers (UNPOL) with the UN Mission in South Sudan (UNMISS). Credit: UN Photo/Eric Kanalstein

As a party to the conflict, South Sudan’s government is not impartial in their position, however they are also not entirely alone in their hesitance. “[An embargo] has to be a last course … we are not there yet,” Mahboub Maalim, Executive Secretary of IGAD, told IPS.

Despite the existing arms in the country and the potential for continued illicit inflows, targeted sanctions by the Security Council may signal deeper commitment to ending the violence and protecting civilians. Nevertheless, neither an embargo nor 4000 additional troops will cure the political divisions among South Sudan’s leadership, which lie at the heart of the conflict.

Paths forward

“The South Sudanese have a string to hang on now … and that is the implementation of the [August 2015] agreement,” Maalim said. “It has had some problems because of the July incident, but it’s going to come on track,” he added referring to violent clashes which took place in South Sudan in July, bringing the country to the brink of all-out war.

However, not everyone agrees on the viability of the previous agreement.

“You have two sides that are not negotiating in good faith … who do not understand how to implement peace agreements they have signed,” said Messfin.

So what is to be done? Beyond the intended value for the protection of civilians, additional troops and restrictions will only go so far without political commitment from the country’s leadership.

Conflict prevention in South Sudan is about strategically applied political leverage, Cedric de Conning, Senior Researcher at the African Centre for the Constructive Resolution of Disputes and the Norwegian Institute of International Affairs, explained to IPS.

A protection force like a reinforced peacekeeping mission can only implement what is agreed to politically, and the warring parties are not committed and remain mistrustful. While immediate action is necessary to save lives, there will eventually need to be a “reset” and a new administration, he continued.

Meanwhile, civil society groups have also reported increased repression of their activities, indicating a further weakening of South Sudan’s social resilience.

“There has been a steady uptick in press freedom violations in South Sudan in recent months,” Murithi Mutiga, East Africa correspondent for the Committee to Protect Journalists (CPJ), told IPS. “We have seen a number of cases of newspaper outlets being arbitrarily closed down, the most prominent cases being the Nation Mirror and the Juba Monitor.”

Press freedom can support the pursuit of a sustained cessation of hostilities, urged CPJ, because accurate and accessible public information allows citizens to better understand how to react to crises without turning to violence. A well-informed population may also be better positioned to define a peaceful future for their country.

The importance of uninhibited civil society for conflict prevention also matches the priorities outlined in two identical resolutions passed by the UN Security Council and General Assembly in April, which recognize pathways to “sustaining peace.” Notably, this includes the development and maintenance of social, political and economic conditions necessary for conflict to be prevented.

South Sudan has experienced persistent violence since 2013, when armed conflict broke out between groups loyal to president Salva Kiir and opposition leader in exile Riek Machar. Fighting escalated along ethnic lines, pitting Dinka against Nuer, until a peace agreement was signed in August 2015. But fighting continued and escalated in July 2016 with a series of clashes in Juba, which left approximately 300 dead. Over the last three years thousands have been killed, over 1.6 million people remain internally displaced, and roughly 4.8 million currently suffer from food insecurity, according to the UN.

While the implementation of September’s joint communiqué will be reviewed with next steps considered at the end of the month, South Sudan’s Humanitarian Response Plan is severely under-funded at just over 50 percent; despite there being no doubt that South Sudan needs immediate assistance.

But this will only serve as a stop-gap against man-made famine. While the Security Council may still unite for the application of an embargo, the fate of South Sudan ultimately lies with its leadership. Their ability to find a lasting agreement, with support from the UN, the African Union, and IGAD, hinges on their willingness to stop the conflict.

“The lives and future of an entire generation hang in the balance,” Tony Lake, Executive Director of UNICEF, said Thursday. “Literally the future of South Sudan.”

Ending Lingering Hunger in a World of Plenty

With malnutrition continuing to afflict one in nine people globally, the UN has appointed 29 global leaders to help tackle the problem head on. ‘’It is unacceptable that in a world of plenty that nearly 800 million people still suffer from hunger, this represents a collective moral and political failure,’’ UN Secretary-General Ban Ki-moon said at […]

Envision Solar Awarded Best Sustainability Award From the San Diego Business Journal's 2016 Manufacturing Awards

SAN DIEGO, CA—(Marketwired – September 27, 2016) – Envision Solar International, Inc. (OTCQB: EVSI) (“Envision Solar,” or the “Company”), the leading renewable energy, media and branding and EV charging product company, announced today that it was named the winner of the Best Sustainability Award in the San Diego Business Journal's 2016 Manufacturing Awards.

The SDBJ's 2016 Manufacturing awards honors San Diego County's best leaders and companies. Envision Solar was selected as a winner from a broad selection of the region's most exciting companies. Other award winners include Solar Turbines Incorporated, D&K Engineering, Inc., Stone Brewing Co. and several other prominent companies.

“We are building a quality company with excellent execution and growth prospects,” said Desmond Wheatley, CEO of Envision Solar. “We sell ground–breaking products to governments and corporations who choose us, because they recognize that what we offer is the best solution available to them. It's wonderful that we have been recognized by the San Diego Business Journal as a winner for our contribution to sustainability.”

Envision Solar is a San Diego based sustainable technology innovation company that produces renewably energized and sustainable products for transportation, security and media platforms. Envision was recently awarded Best Product of the Year in the 8th Annual Golden Bridge Awards in the Energy Industry Innovations category.

About Envision Solar International, Inc.

Envision Solar designs, manufactures and deploys unique, renewably energized, EV charging and media and branding systems. The Company's products include the patented EV ARC™ and Solar Tree® product lines. All of the Company's products can be enhanced with EnvisionTrak™ patented solar tracking, ARC Technology™ energy storage, SunCharge™ Electric Vehicle Charging Stations and digital advertising packages.

Based in San Diego, the company integrates the highest quality components into its Made in America products. Envision Solar is listed on the OTC Bulletin Board under the symbol [EVSI]. For more information, visit www.envisionsolar.com or call 866–746–0514.

Forward–Looking Statements

This Press Release may contain forward–looking statements regarding future events or our expected future results that are subject to inherent risks and uncertainties. All statements in this Report other than statements of historical facts are forward looking statements. Forward looking statements are generally accompanied by terms or phrases such as “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “target,” “plan,” “intend,” “seek,” “goal,” “will,” “should,” “may,” or other words and similar expressions that convey the uncertainty of future events or results. Statements contemplating or making assumptions regarding actual or potential sales, market size and demand, prospective business contracts, customer orders, trends or operating results also constitute forward looking statements. Our actual results may differ substantially from those indicated in forward looking statements because our business is subject to significant economic, competitive, regulatory, business and industry risks which are difficult to predict and many of which are beyond our control. Our operating results, financial condition and business performance may be adversely affected by a general decline in the economy, unavailability of capital or financing for our prospective customers to purchase products and services from us, competition, changes in regulations, a decline in the demand for solar energy, a lack of profitability, a decline in our stock price, and other risks. We may not have adequate capital, financing or cash flow to sustain our business or implement our business plans. Current results and trends are not necessarily indicative of future results that we may achieve.

NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms

FORT WASHINGTON, PA—(Marketwired – September 26, 2016) – Myeloproliferative Neoplasms (MPN) are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. These cancers — Myelofibrosis, Essential Thrombocythemia (ET), and Polycythemia vera (PV) — affect approximately 13,000, 134,000, and 148,000 patients in the United States, respectively.[1]

To provide clinicians with the most up–to–date and comprehensive treatment recommendations, the National Comprehensive Cancer Network® (NCCN®) today published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for MPN to specifically outline diagnosis, treatment, and supportive care strategies for Myelofibrosis. Myelofibrosis is a type of MPN that is the result — in most cases — of one of three genetic mutations within the JAK2 signaling pathway. Comprehensive recommendations for the management of ET and PV will be included in the subsequent versions of the NCCN Guidelines® for MPN.

NCCN Guidelines document evidence–based consensus–driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive care services that are most likely to lead to optimal outcomes.

“The management of MPNs has been variable in the past and largely driven by review articles and individual opinions. The NCCN Guidelines Panel for MPN hopes these inaugural Guidelines will help leverage the evidence base in MPN care for clear, well–informed, treatment guidelines to hopefully improve quality of care and provide better outcomes for patients with MPN,” said Ruben A. Mesa, MD, FACP, Mayo Clinic Cancer Center, Chair of the NCCN Guidelines Panel for MPN.

Dr. Mesa will present the new NCCN Guidelines in an educational setting during the NCCN 11th Annual Congress: Hematologic Malignancies™ on Friday, September 30, in a session titled, “Myeloprofilerative Neoplasms and Myelofibrosis: Evolving Management.” To register, visit NCCN.org/HEM.

With the publication of the NCCN Guidelines for MPN, the library of NCCN Guidelines now includes 63 clinical guidelines detailing sequential management decisions and interventions that currently apply to 97 percent of cancers affecting people in the United States, as well as cancer prevention, detection and risk reduction, and age–related recommendations.

Available free–of–charge to registered users of NCCN.org and through the Virtual Library of NCCN Guidelines Mobile Apps, NCCN Guidelines help oncologists make the major clinical decisions encountered in managing their patients by providing ready access to synthesized information. The NCCN Guidelines provide recommendations for appropriate care for most, but not all patients; however, all individual patient circumstances must be considered when applying these recommendations.

To access the NCCN Guidelines for MPN, visit NCCN.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not–for–profit alliance of 27 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high–quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision–makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana–Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes–Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt–Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.

[1] Metha J, Wang H, Iqbal SU, Mesa R, Epidemiology of myeloproliferative neoplasms in the United States, Leuk Lymph 2014;55:595–600.

The following files are available for download: